| Literature DB >> 27430902 |
Giuseppe Bellelli1,2,3, Alessandro Morandi4,5, Simona G Di Santo6, Andrea Mazzone7, Antonio Cherubini8, Enrico Mossello9, Mario Bo10, Angelo Bianchetti11, Renzo Rozzini12, Ermellina Zanetti13, Massimo Musicco14,15, Alberto Ferrari16,17, Nicola Ferrara18,19,20, Marco Trabucchi4,21,22.
Abstract
BACKGROUND: To date, delirium prevalence in adult acute hospital populations has been estimated generally from pooled findings of single-center studies and/or among specific patient populations. Furthermore, the number of participants in these studies has not exceeded a few hundred. To overcome these limitations, we have determined, in a multicenter study, the prevalence of delirium over a single day among a large population of patients admitted to acute and rehabilitation hospital wards in Italy.Entities:
Keywords: 4AT; Delirium; Hospital; Multicenter; Prevalence
Mesh:
Year: 2016 PMID: 27430902 PMCID: PMC4950237 DOI: 10.1186/s12916-016-0649-8
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Fig. 1Disposition of participants in the study
Participant characteristics according to diagnosis of delirium
| Delirium ( | No delirium ( |
| |
|---|---|---|---|
| Age, years | 84.8 ± 6.7 | 81.1 ± 7.6 | < .001 |
| Female gender, | 249 (58.0) | 833 (57.9) | 1.000 |
| Education, years | 6.2 ± 3.6 | 6.8 ± 3.8 | .006 |
| ADL before admission, median score (IQR) | 1 (0–4) | 5 (2–6) | < .001 |
| 0 functions spared | 186 (43.4) | 155 (10.8) | |
| 1 function spared | 66 (15.4) | 174 (12.1) | < .001 |
| 2 to 5 functions spared | 118 (27.5) | 471 (33.8) | |
| 6 functions spared | 59 (13.8) | 638 (44.4) | |
| Nutritional status, | |||
| Well nourished | 156 (36.4) | 949 (66.0) | < .001 |
| At risk of malnutrition | 215 (50.1) | 414 (28.8) | |
| Malnourished | 58 (13.5) | 75 (5.2) | |
| Charlson index (excluding dementia), median score (IQR) | 2 (1–4) | 2 (1–4) | .87 |
| Dementia, | 227 (52.9) | 222 (15.4) | < .001 |
| No. of drugs, on admission, median score (IQR) | 5 (4–-7) | 5 (3–7) | .56 |
| Diuretics, | 202 (47.1) | 727 (50.6) | .22 |
| Antihypertensive drugs, | 241 (56.2) | 939 (65.3) | .001 |
| Antiplatelet drugs, | 174 (49.6) | 612 (42.6) | .47 |
| Antiarrhythmic drugs, | 39 (9.1) | 173 (12.0) | .10 |
| Statins/lipid lowering drugs, | 45 (10.5) | 297 (20.7) | < .001 |
| Antidiabetics (including insulin), | 72 (16.8) | 284 (19.7) | .18 |
| Antiulcer drugs, | 270 (62.9) | 980 (68.2) | .04 |
| Antibiotics, | 186 (43.4) | 433 (30.1) | < .001 |
| Benzodiazepines, | 93 (21.7) | 360 (25.0) | .16 |
| Antipsychotics, | 107 (28.3) | 119 (9.1) | < .001 |
| Antidepressants, | 112 (26.1) | 278 (19.3) | .003 |
| Antiepileptics, | 32 (7.5) | 93 (6.5) | .51 |
| AChE-I/memantine, | 15 (3.5) | 24 (1.7) | .03 |
| Feeding tubes (NT or PEG), | 20 (4.7) | 20 (1.4) | < .001 |
| Venous catheter, | 244 (56.9) | 694 (42.0) | < .001 |
| Urinary catheter, | 199 (46.4) | 340 (23.6) | < .001 |
| Physical restraints, | 268 (62.5) | 427 (29.7) | < .001 |
Data are expressed as mean + SD unless otherwise specified; IQR interquartile range, p value: significance at one-way ANOVA or t test and at Kruskal-Wallis test or Mann-Whitney U test for normally and abnormally distributed data, respectively
ADL Activities of Daily Living score, AChE-I acetylcholinesterase inhibitors, NT nasogastric tube, PEG percutaneous endoscopic gastrostomy
Participant characteristics according to settings of admission
| Rehabilitation ( | Geriatrics ( | Orthopedics ( | Neurology ( | Int. Medicine ( |
| |
|---|---|---|---|---|---|---|
| Age, years | 80.4 ± 7.7b,d | 83.2 ± 7.1 a,c,d,e | 80.8 ± 8.4 b,d | 77.7 ± 7.2 a,b,c,e | 80.7 ± 7.7 b,d | <0.001 |
| Female gender, | 153 (61.2) | 679 (58.8) | 72 (67.3)e | 81 (51.3) | 97 (49.0)c | 0.005 |
| Education, years | 7.3 ± 3.7b,e | 6.5 ± 3.8 a | 7.2 ± 4.5 | 7.0 ± 3.7 | 6.9 ± 3.4a | 0.004 |
| ADL before admission, mean score | 5 (1–6)b | 4 (1–6)a,c,d,e | 5 (3–6)b | 5 (2–6)b | 5 (2–6)b | <0.001 |
| 0 functions spared, | 32 (12.8) | 255 (22.1) | 8 (7.5) | 22 (13.9) | 24 (12.1) | |
| 1 function spared, | 34 (13.6) | 156 (13.5) | 9 (8.4) | 16 (10.1) | 25 (12.6) | <0.001 |
| 2 to 5 functions spared, | 92 (36.8) | 349 (30.2) | 41 (38.3) | 45 (28.5) | 62 (31.3) | |
| 6 functions spared, | 92 (36.8) | 394 (34.1) | 49 (45.8) | 75 (47.5) | 87 (43.9) | |
| Nutritional status, | ||||||
| Well nourished | 171 (68.4)b,d | 601 (52.1)a,d,e | 61 (57.0)d | 130 (82.3)a,b,c | 142 (71.7)b | <0.001 |
| At risk of malnutrition | 60 (24.0)a | 457 (39.6)b,d,e | 37 (34.6)d | 27 (17.1)b,c | 48 (24.2)b | |
| Malnourished | 19 (7.6)d | 96 (8.3)d | 9 (8.4)d | 1 (0.6)a,b,c | 8 (4.0) | |
| Charlson index (excluding dementia) | 1 (0–3) b,e | 3 (1–5) a,c,d | 1 (0–3) b,e | 2 (1–3)b,e | 3 (1–4) a,c,d | <0.001 |
| Dementia, | 50 (20.0)d | 304 (26.3)d | 18 (16.8) | 60 (38.0)a,b,e | 33 (16.7) d | <0.001 |
| No. drugs, on admission | 5 (3–6)e | 5 (4–7)c | 4 (3–6)b | 5 (3–6)e | 6 (4–7)a,d | <0.001 |
| Diuretics, | 122 (48.8)d | 624 (54.1)c,e | 36 (33.6)b | 80 (31.6)a,b,e | 97 (49.0)d | <0.001 |
| Antihypertensive, | 157 (62.8) | 723 (62.7) | 62 (57.9) | 99 (62.7) | 139 (70.2) | 0.228 |
| Antiplatelet drugs, | 93 (37.2)d | 473 (41.0)d | 37 (34.6)d | 80 (31.6)a,b,c,e | 97 (49.0)d | <0.001 |
| Antiarrhythmic drugs, | 27 (10.8) | 139 (12.0) | 7 (6.5) | 11 (7.0) | 28 (14.1) | 0.106 |
| Statins/lipid lowering drugs, | 56 (22.4) | 183 (15.9)d | 15 (14.0) | 41 (25.9)b | 47 (23.7) | 0.001 |
| Antidiabetics (including insulin), | 34 (13.6) | 227 (19.7) | 18 (16.8) | 30 (19.0) | 47 (23.7) | 0.082 |
| Antiulcer drugs, | 166 (66.4) | 783 (67.9)d | 74 (69.2) | 87 (55.1)b,e | 140 (70.7)d | 0.017 |
| Antibiotics, | 26 (10.4)b,c,e | 448 (38.8)a,d | 38 (35.5)a,d | 22 (13.9)b,c,e | 85 (42.9) a,d | <0.001 |
| Benzodiazepines, | 74 (29.6) | 259 (22.4) | 25 (23.4) | 51 (32.3) | 44 (22.2) | 0.018 |
| Antipsychotics, | 29 (11.6)d | 163 (14.1)d | 10 (9.3)d | 42 (26.6)a,b,c,e | 19 (9.6)d | <0.001 |
| Antidepressants, | 60 (24.0) | 226 (19.6)d | 22 (20.6) | 50 (31.6)b,e | 32 (12.6)d | 0.003 |
| Antiepileptics, | 24 (9.6)c,d | 61 (5.3)d | 0a,d | 34 (21.5)a,b,c,e | 6 (3.0)d | <0.001 |
| AChE-I/memantine, | 4 (1.6) | 22 (1.9)d | 1 (0.9) | 10 (6.3)b | 1 (1.0) | 0.003 |
| Feeding tubes (NT or PEG), | 3 (1.2) | 23 (2.0) | 4 (3.7) | 5 (3.2) | 5 (2.5) | 0.492 |
| Venous catheter, | 26 (10.4)b,c,d,e | 577 (50.0)a,c,d,e | 75 (70.1)a,b,d | 34 (21.5)a,b,c,e | 136 (68.7) a,b,d | <0.001 |
| Urinary catheter, | 28 (11.2)b,c,d,e | 364 (31.5)a,c | 66 (61.7)a,b,d,e | 35 (22.2)a,c | 46 (23.2)a,c | <0.001 |
| Physical restraints, | 68 (27.2)b | 465 (40.3)a | 44 (41.1) | 52 (32.9) | 62 (31.1) | <0.001 |
Data are expressed as mean + SD unless otherwise specified; IQR interquartile range, ADL Activities of Daily Living score, AChE-I acetylcholinesterase inhibitors, NT nasogastric tube, PEG percutaneous endoscopic gastrostomy
p denotes significance on ANOVA for continuous or chi-square for categorical variables. Where significant group effects were detected, either Turkey or Dunn or Bonferroni tests indicated significant post hoc differences between individual groups, as follows:
aSignificant difference with Rehabilitation group
bSignificant difference with Geriatrics group
cSignificant difference with Orthopedics group
dSignificant difference with Neurology group
eSignificant difference with Internal Medicine group
Fig. 2Prevalence of delirium according to different settings
Univariate and multivariate analyses of factors associated with delirium
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| Number | OR | 95 % CI |
| OR | 95 % CI |
| |
| Age | 1.07 | 1.05–1.09 | <.001 | 1.03 | 1.01–1.05 | .006 | |
| Female sex | 180/785 | .99 | .80–1.24 | .97 | -- | -- | -- |
| Education, years | .96 | .93–.99 | .008 | 1.00 | .97–1.04 | .77 | |
| Rehabilitation wards | 35/250 | Ref | Ref | ||||
| Geriatrics wards | 285/1154 | 2.02 | 1.38–2.95 | <.001 | 1.15 | .72–1.83 | .56 |
| Orthopedic surgery wards | 22/107 | 1.59 | .88–2.87 | 0.12 | -- | -- | -- |
| Neurology wards | 45/158 | 2.45 | 1.49–4.02 | <.001 | 2.00 | 1.10–3.64 | .02 |
| Internal Medicine wards | 42/198 | 1.65 | 1.01–2.71 | .05 | 1.40 | .77–2.57 | .27 |
| ADL (functions lost) | 1.45 | 1.38–1.53 | <.001 | 1.19 | 1.12–1.27 | <.001 | |
| Dementia (yes/no) | 243/465 | 7.16 | 5.64–9.08 | <.001 | 3.25 | 2.41–4.38 | <.001 |
| Malnutrition (yes/no) | 58/133 | 2.84 | 1.98–4.08 | <.001 | 2.01 | 1.29–3.14 | .002 |
| Antihypertensives (yes/no) | 241/1180 | .68 | .55–.85 | .001 | .84 | .64–1.09 | .18 |
| Statins/lipid lowering (yes/no) | 45/342 | .45 | 0.32–0.63 | <.001 | .79 | .53–1.17 | .23 |
| Antibiotics (yes/no) | 186/619 | 1.78 | 1.42–2.22 | <.001 | 1.24 | 0.93–1.64 | .14 |
| Antipsychotics (yes/no) | 132/263 | 4.43 | 3.38–5.82 | <.001 | 2.03 | 1.45–2.82 | <.001 |
| Antidepressants (yes/no) | 112/390 | 1.47 | 1.15–1.90 | .003 | 1.03 | .76–1.41 | .83 |
| Antiulcer drugs (yes/no) | 270/1250 | .79 | .63–.99 | .04 | .86 | .65–1.13 | .27 |
| AChE-I/memantine (yes/no) | 15/39 | 2.14 | 1.11–4.11 | .03 | .91 | .42–1.97 | .81 |
| Feeding tubes (NT or PEG) (yes/no) | 20/40 | 3.47 | 1.85–6.51 | <.001 | 2.51 | 1.11–5.66 | .03 |
| Peripheral venous catheters (yes/no) | 244/848 | 1.82 | 1.47–2.27 | <.001 | 1.41 | 1.06–1.87 | .02 |
| Urinary catheters (yes/no) | 199/539 | 2.79 | 2.23–3.50 | <.001 | 1.73 | 1.30–2.29 | <.001 |
| Physical restraints (yes/no) | 268/695 | 3.94 | 3.15–4.94 | <.001 | 1.84 | 1.40–2.40 | <.001 |
OR odds ratio, 95 % CI 95 % confidence interval, Ref reference value for the hospital wards, ADL Activities of Daily Living score, AChE-I acetylcholinesterase inhibitors, NT nasogastric tube, PEG percutaneous endoscopic gastrostomy